Citius Pharmaceuticals
CTXR
34 hedge funds and large institutions have $773K invested in Citius Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 5 closing their positions.
921% more call options, than puts
Call options by funds: $143K | Put options by funds: $14K
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
10% more funds holding
Funds holding: 31 → 34 (+3)
5.06% less ownership
Funds ownership: 8.73% → 3.67% (-5.1%)
48% less capital invested
Capital invested by funds: $1.48M → $773K (-$704K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$120K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$60.9K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$47.4K |
| 4 |
Jane Street
New York
|
+$26.3K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$17.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Heights Capital Management
San Francisco,
California
|
-$254K |
| 2 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$242K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$233K |
| 4 |
BCA
Bay Colony Advisors
Concord,
Massachusetts
|
-$26.2K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$5.89K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PGAM
26
Princeton Global Asset Management
Princeton,
New Jersey
| $198 | – | – | – |
|
27
JP Morgan Chase
New York
| $149 | – | – | – |
|
|
SWIM
28
Smallwood Wealth Investment Management
Red Bank,
New Jersey
| $148 | – | – | – |
|
|
QC
29
Quent Capital
New York
| $134 | +$151 | +108 | New |
|
30
BNP Paribas Financial Markets
Paris,
France
| $133 | – | – | – |
|
|
AAP
31
Arax Advisory Partners
Denver,
Colorado
| $104 | +$117 | +84 | New |
|
|
FDCDDQ
32
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $99 | – | – | – |
|
|
FC
33
Fairscale Capital
Nashua,
New Hampshire
| $52 | – | – | – |
|
34
Wells Fargo
San Francisco,
California
| $50 | +$56 | +40 | New |
|
|
HCM
35
Heights Capital Management
San Francisco,
California
| – | -$254K | -159,898 | Closed |
|
|
BCA
36
Bay Colony Advisors
Concord,
Massachusetts
| – | -$26.2K | -16,500 | Closed |
|
37
Group One Trading
Chicago,
Illinois
| – | -$1.03K | -649 | Closed |
|
38
Raymond James Financial
St Petersburg,
Florida
| – | -$359 | -226 | Closed |
|
|
LFG
39
Larson Financial Group
St Louis,
Missouri
| – | -$72 | -45 | Closed |
|
CTXR Hedge Fund Activity: Q3 2025 in Review
34 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q3 2025, worth a combined $773K — down 48% from $1.48M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CTXR positions and 5 closed out — a net gain of 3 holders — while 9 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $120K. The largest seller was Heights Capital Management, exiting entirely with an estimated $254K sold.
- 34 institutional investors held Citius Pharmaceuticals (CTXR) as of Q3 2025, up from 31 in Q2 2025.
- Funds reported $773K of Citius Pharmaceuticals stock for Q3 2025, down 48% quarter-over-quarter.
- 8 funds opened new Citius Pharmaceuticals positions in Q3 2025 and 5 closed out, a net change of +3 holders.
- The largest Citius Pharmaceuticals buyer in Q3 2025 was Vanguard Group, an estimated $120K added.
- The largest Citius Pharmaceuticals seller in Q3 2025 was Heights Capital Management, an estimated $254K sold.
Based on aggregated 13F filings for Q3 2025.